Clark, Peter E <br/><br/>
The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.  [electronic resource] 

 -  Kidney international  Nov 2009 
 - 939-45 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Review 
<br/><br/><label>ISSN: </label>1523-1755 
<br/><br/><label>Standard No.: </label>10.1038/ki.2009.296  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--therapeutic use<br/>Antineoplastic Agents--adverse effects<br/>Aryl Hydrocarbon Receptor Nuclear Translocator--genetics<br/>Carcinoma, Renal Cell--drug therapy<br/>Drug Design<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Hypoxia-Inducible Factor 1, alpha Subunit--genetics<br/>Kidney Neoplasms--genetics<br/>Protein Kinase Inhibitors--therapeutic use<br/>Protein Kinases--drug effects<br/>Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>TOR Serine-Threonine Kinases<br/>Translational Research, Biomedical<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Von Hippel-Lindau Tumor Suppressor Protein--genetics